ÔçÒÒŮѸÀ×

    1. <form id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></form>
      <address id=SSjMaZxIp><nobr id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></nobr></address>

      Current Value of Holding

      $0

      Shares

      0

      % of Portfolio

      0.00%

      Average Buy Price

      $96.5

      Avg closing price
      Price range

      2 Jefferies Group Novartis AG Trades

      Jefferies Group started to build up the position in Novartis AG in Q4 2023. Since then they sold 49.4k shares. The investor sold all their shares in Q1 2024 and doesn't own any shares in Novartis AG anymore.

      Avg closing price
      Price range
      Sold -49.4k shares Q1 2024
      Avg closing price $102.53
      Price range $95.27 - $108.47
      New holding (+49.4k shares) Q4 2023
      Avg closing price $96.53
      Price range $92.27 - $101.54

      News about Novartis AG - ADR and Jefferies Group

      Novartis phase III data confirm sustained efficacy and long©¤term safety of oral remibrutinib in chronic spontaneous urticaria

      Novartis phase III data confirm sustained efficacy and long©¤term safety of oral remibrutinib in chronic spontaneous urticaria

      ¡­ , and multiple sclerosis4-8. Novartis will submit remibrutinib for approval ¡­ effective oral option within the Novartis immunology portfolio, which current...

      EIN News Pharmaceuticals EIN News Pharmaceuticals, over 1 year ago
      Sandoz Group: Novartis Spinoff With A Double-Digit EBITDA CAGR Through 2028

      Sandoz Group: Novartis Spinoff With A Double-Digit EBITDA CAGR Through 2028

      Sandoz is a global leader in the generics and biosimilars sector. Click here to read why I think spinning off SDZNY stock was a good move by Novartis.

      Seeking Alpha Seeking Alpha, almost 2 years ago
      Pharming announces the first commercial shipments of Joenja? (leniolisib) to patients in the U.S.

      Pharming announces the first commercial shipments of Joenja? (leniolisib) to patients in the U.S.

      LEIDEN, Netherlands , April 11, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) announces the first commerci...

      PR Newswire Asia (English) PR Newswire Asia (English), over 2 years ago
      Pharming announces US FDA approval of Joenja? (leniolisib) as the first and only treatment indicated for APDS

      Pharming announces US FDA approval of Joenja? (leniolisib) as the first and only treatment indicated for APDS

      APDS (activated phosphoinositide 3-kinase delta (PI3K¦Ä) syndrome) is a rare and progressive primary immunodeficiency Joenja? is a targeted treatment of APDS ...

      PR Newswire Asia (English) PR Newswire Asia (English), over 2 years ago

      Embed chart

      Easily embed the chart on your blog or website ¨C it will always update automatically!

      HoMEÔçÒÒŮѸÀ×